Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
31,500
Employees31,500
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
31,500
Employees31,500

AMGN Key Statistics

Market cap
233.29B
Market cap233.29B
Price-Earnings ratio
27.15
Price-Earnings ratio27.15
Dividend yield
2.24%
Dividend yield2.24%
Average volume
2.37M
Average volume2.37M
High today
$439.70
High today$439.70
Low today
$430.72
Low today$430.72
Open price
$438.75
Open price$438.75
Volume
1.11M
Volume1.11M
52 Week high
$447.03
52 Week high$447.03
52 Week low
$269.77
52 Week low$269.77

Stock Snapshot

The current Amgen(AMGN) stock price is $431.52, with a market capitalization of 233.29B. The stock trades at a price-to-earnings (P/E) ratio of 27.15 and offers a dividend yield of 2.24%.

On 2026-08-28, Amgen(AMGN) stock traded between a low of $430.72 and a high of $439.70. Shares are currently priced at $431.52, which is +0.2% above the low and -1.9% below the high.

The Amgen(AMGN)'s current trading volume is 1.11M, compared to an average daily volume of 2.37M.

During the past year, Amgen(AMGN) stock moved between $269.77 at its lowest and $447.03 at its peak.

During the past year, Amgen(AMGN) stock moved between $269.77 at its lowest and $447.03 at its peak.

AMGN News

TipRanks 3h
Amgen’s Pediatric Psoriasis Study Wrap-Up: What Apremilast Safety Data Means for Investors

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Amgen’s latest psoriasis study update spotlights apremilast (AMG 407) for kids and teens....

Simply Wall St 5h
What Could Amgen Gain From Tezspire’s Phase III EoE Success?

Amgen (NasdaqGS:AMGN) and AstraZeneca reported positive Phase III results for Tezspire in eosinophilic esophagitis, supporting a potential label expansion. The...

What Could Amgen Gain From Tezspire’s Phase III EoE Success?
TipRanks 1d
Amgen’s AMG 691 Phase 1 Trial Targets Key Growth in Asian Markets

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Amgen Inc. (AMGN) has started a new Phase 1 trial called “A Phase 1, Open-Label, Single-D...

Analyst ratings

47%

of 36 ratings
Buy
38.9%
Hold
47.2%
Sell
13.9%

More AMGN News

Nasdaq 1d
AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study

AstraZeneca AZN and its partner Amgen AMGN jointly announced positive top-line data from the late-stage CROSSING study, which evaluated Tezspire (tezepelumab) i...

AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study
Benzinga 1d
AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease

On Thursday, AstraZeneca Plc (NYSE:PLC) and Amgen Inc. (NASDAQ:AMGN) shared topline data from the Phase 3 CROSSING trial of Tezspire (tezepelumab) administered...

AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease
TipRanks 1d
Amgen, AstraZeneca announce Crossing trial showed ‘meaningful’ improvements

Positive high-level results from the Phase III CROSSING trial in patients with eosinophilic esophagitis showed that AstraZeneca (AZN) and Amgen’s (AMGN) TEZSPIR...

Simply Wall St 3d
Is Amgen Refocusing Its R&D Portfolio With The Exit From TScan’s Crohn’s Deal?

In August 2026, TScan Therapeutics disclosed that Amgen elected to terminate their May 2023 Research Collaboration and License Agreement focused on Crohn's dise...

Is Amgen Refocusing Its R&D Portfolio With The Exit From TScan’s Crohn’s Deal?
TipRanks 4d
Amgen Extends MariTide Study In Obesity And Diabetes, Keeping Investor Focus On Long-Term Potential

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident inv...

Nasdaq 6d
Which Biotech ETF Is a Better Buy: Concentrated Bet or Broad Basket?

Key Points Invesco Nasdaq Biotechnology ETF has a significantly lower expense ratio and double the dividend yield of VanEck Biotech ETF. VanEck Biotech ETF ma...

Which Biotech ETF Is a Better Buy: Concentrated Bet or Broad Basket?

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.